IBOV 176,641 ▲ 0.51% IPSA 11,024 ▲ 1.05% IPC MEX 66,514 ▲ 0.82% MERVAL 3,229,324 ▼ 0.18% COLCAP 2,298.73 ▼ 0.39% BVL PERÚ 56,428.20 ▲ 1.32% USD/BRL5.07▼ 1.23% USD/MXN17.42▼ 0.65% USD/CLP925.95▼ 0.75% USD/COP3,257▼ 0.16% USD/PEN3.39▼ 0.62% USD/ARS1,470▼ 0.88% USD/UYU40.23▲ 0.99% USD/PYG6,039▲ 1.12% USD/BOB10.35▲ 6.04% USD/DOP58.31▲ 0.39% USD/CRC448.93▲ 1.31% USD/GTQ7.62▲ 2.07% USD/HNL26.73▲ 1.38% USD/NIO36.62▲ 0.63% USD/VES722.19▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 0.64% USD/TTD6.75▲ 1.19% EUR/BRL5.79▼ 0.44% BRENT 85.21 ▲ 2.29% WTI 79.76 ▲ 2.07% IRON ORE 161.91 — — COPPER 6.37 ▲ 2.15% GOLD 4,058 ▲ 1.53% SILVER 59.12 ▲ 2.57% SOY 1,191 ▼ 0.96% CORN 459.50 ▲ 4.97% WHEAT 644.00 ▲ 2.71% COFFEE 327.00 ▼ 4.22% SUGAR 14.92 ▲ 1.15% ORANGE JUICE 140.90 ▼ 1.16% COTTON 81.68 ▲ 2.32% COCOA 5,936 ▲ 4.21% BEEF 231.58 ▼ 1.34% CATTLE 349.63 ▼ 1.33% LITHIUM 71.58 ▲ 1.91% PETR4 40.66 — 0.00% VALE3 74.01 ▲ 1.59% ITUB4 43.63 ▲ 0.25% BBDC4 18.63 ▼ 0.75% ABEV3 15.81 ▼ 0.13% BBAS3 20.59 ▲ 1.73% B3SA3 15.33 ▲ 1.39% WEGE3 44.20 ▼ 0.43% PRIO3 57.57 ▲ 0.65% SUZB3 41.11 ▼ 0.92% RENT3 40.54 ▲ 0.85% AZZA3 18.85 ▼ 1.93% CSAN3 3.89 ▼ 0.26% RAIZ4 0.31 ▼ 6.06% PCAR3 2.45 ▼ 5.41% GMAT3 3.96 ▲ 0.51% PSSA3 54.29 ▲ 0.46% CVCB3 1.38 ▲ 10.40% POSI3 3.99 — 0.00% SLCE3 13.81 ▼ 0.43% NATU3 8.55 ▼ 0.58% BRKM5 6.83 ▼ 1.59% RANI3 8.01 ▲ 0.75% CSNA3 5.20 ▼ 0.76% CMIN3 5.10 ▼ 6.42% USIM5 8.23 ▼ 1.79% GGBR4 23.32 ▲ 2.19% ENEV3 27.17 ▲ 1.08% CPFE3 47.20 ▲ 0.77% CMIG4 11.20 ▲ 1.17% EQTL3 40.95 ▲ 1.84% LREN3 14.29 ▲ 0.99% VIVT3 35.52 ▲ 2.27% RAIL3 14.13 ▲ 0.14% KLABIN 17.32 ▼ 0.92% RAIA DROGASIL 18.60 ▲ 2.20% RDOR3 36.05 ▲ 1.38% HAPV3 11.19 ▲ 6.98% FLRY3 16.41 ▲ 1.61% SMTO3 16.12 ▼ 1.53% UGPA3 30.11 ▼ 2.65% VBBR3 33.30 ▲ 1.65% BBSE3 40.39 ▲ 0.27% BPAC11 57.95 ▲ 0.75% CURY3 33.59 ▲ 1.42% AERI3 2.07 ▼ 0.48% VIVARA 23.43 ▲ 1.38% COMPASS 25.20 ▲ 1.74% VAMOS 3.15 ▲ 4.30% SANB11 27.34 ▼ 0.11% ASAI3 8.66 ▼ 0.57% SBSP3 30.34 ▼ 0.10% WALMEX 49.32 ▼ 0.66% GMEXICO 199.61 ▲ 2.06% FEMSA 232.52 ▲ 3.18% CEMEX 22.24 ▲ 2.11% GFNORTE 186.00 ▲ 2.16% BIMBO 56.55 ▲ 1.22% TELEVISA 9.49 ▼ 1.25% AMX 22.83 ▲ 1.06% GAP 394.05 ▼ 3.46% ASUR 275.61 ▼ 1.09% OMA 235.49 ▲ 0.93% KOF 180.00 ▼ 0.92% GRUMA 280.31 ▼ 0.38% KIMBER 38.53 ▲ 0.81% SQM-B 67,900 ▲ 1.03% COPEC 6,210 ▲ 2.52% BSANTANDER 78.64 ▲ 0.56% FALABELLA 5,875 ▼ 0.51% ENELAM 85.75 ▲ 1.84% CENCOSUD 2,040 — 0.00% CMPC 1,103 ▲ 2.32% BANCO CHILE 189.50 ▲ 2.43% LATAM AIR 24.90 — 0.00% YPF 77,775 ▲ 0.78% GGAL 7,910 ▼ 2.10% PAMPA 5,230 ▲ 0.10% TXAR 662.00 ▼ 0.38% ALUAR 949.00 ▼ 1.61% TGS 9,710 ▲ 1.46% CEPU 2,327 ▲ 0.35% MIRGOR 16,750 ▼ 1.47% COME 45.75 ▲ 2.17% LOMA NEGRA 3,533 ▲ 1.00% BYMA 301.00 ▼ 2.35% TELECOM ARG 4,333 ▲ 1.94% ECOPETROL 16.16 ▲ 1.76% BANCOLOMBIA 82.10 ▲ 2.09% GRUPO AVAL 4.95 ▲ 0.81% CREDICORP 392.24 ▲ 0.78% SOUTHERN COPPER 182.38 ▲ 4.50% BUENAVENTURA 31.03 ▲ 4.06% MERCADOLIBRE 1,874 ▲ 0.35% NUBANK 13.99 ▲ 2.34% XP 16.87 ▲ 3.05% PAGSEGURO 9.28 — 0.00% STONE 11.30 ▲ 1.35% GLOBANT 30.92 ▼ 3.74% TECNOGLASS 44.19 ▲ 3.15% GAP AIRPORT 225.95 ▼ 2.93% ASUR 275.61 ▼ 1.09% OMA AIRPORT 107.64 ▲ 1.42% AMX ADR 26.18 ▲ 0.58% FEMSA ADR 133.17 ▲ 3.22% CEMEX ADR 12.80 ▲ 2.81% PETROBRAS ADR 17.92 ▲ 0.22% VALE ADR 14.59 ▲ 2.89% ITAU ADR 8.55 ▲ 0.94% SANTANDER BR 5.40 ▲ 0.84% AMBEV ADR 3.09 ▲ 0.98% CSN 1.04 ▲ 0.49% GERDAU 4.61 ▲ 2.67% LATAM ADR 53.51 ▲ 0.34% BTC 64,942 ▲ 4.34% ETH 1,887 ▲ 6.38% SOL 77.68 ▲ 3.77% XRP 1.11 ▲ 4.19% BNB 581.34 ▲ 2.60% ADA 0.16 ▲ 4.75% DOGE 0.07 ▲ 3.48% AVAX 6.65 ▲ 3.19% LINK 8.32 ▲ 5.73% DOT 0.85 ▲ 1.85% LTC 45.43 ▲ 4.46% BCH 236.54 ▲ 0.13% TRX 0.33 ▲ 0.53% XLM 0.18 ▲ 2.23% HBAR 0.07 ▲ 1.03% NEAR 2.01 ▲ 4.55% ATOM 1.56 ▲ 1.56% AAVE 98.70 ▲ 4.60% SELIC 14.25% EMBRAER 82.49 ▼ 0.63% EMBRAER ADR 64.91 ▲ 0.67% JBS 11.83 ▲ 0.25% JBS BDR 59.75 ▼ 1.42% MBRF3 16.09 ▲ 2.35% MBRFY 3.14 ▲ 2.95% INTER 5.70 ▲ 0.89% EGX 52,299 ▼ 0.59% USD/ZAR16.36▼ 0.70% USD/NGN 1,381 — 0.00% NIKKEI 67,744 ▲ 0.74% CSI300 4,797 ▲ 2.15% HSI 24,341 ▲ 0.52% NIFTY 24,052 ▼ 0.66% KOSPI 6,857 ▲ 0.73% JCI 6,040 ▲ 0.03% USD/JPY 162.20 — 0.00% USD/CNY 6.7624 — 0.00% DAX 25,147 ▲ 0.13% CAC 8,367 ▲ 0.03% FTSE 10,529 ▲ 0.30% MIB 52,863 ▲ 0.10% IBEX 19,357 ▲ 0.11% STOXX 642.10 ▲ 0.17% EUR/USD1.14▲ 0.38% GBP/USD1.34▲ 0.06% SPX 7,544 ▲ 0.38% DJI 52,508 ▲ 0.02% NDX 29,586 ▲ 1.10% RUT 2,965 ▲ 0.39% TSX 35,321 ▲ 0.19% VIX 16.50 ▼ 3.85% USD/CAD1.41▼ 0.70% US10Y 4.5850 ▼ 0.52% IBOV 176,641 ▲ 0.51% IPSA 11,024 ▲ 1.05% IPC MEX 66,514 ▲ 0.82% MERVAL 3,229,324 ▼ 0.18% COLCAP 2,298.73 ▼ 0.39% BVL PERÚ 56,428.20 ▲ 1.32% USD/BRL 5.07 ▼ 1.23% USD/MXN 17.42 ▼ 0.65% USD/CLP 925.95 ▼ 0.75% USD/COP 3,257 ▼ 0.16% USD/PEN 3.39 ▼ 0.62% USD/ARS 1,470 ▼ 0.88% USD/UYU 40.23 ▲ 0.99% USD/PYG 6,039 ▲ 1.12% USD/BOB 10.35 ▲ 6.04% USD/DOP 58.31 ▲ 0.39% USD/CRC 448.93 ▲ 1.31% USD/GTQ 7.62 ▲ 2.07% USD/HNL 26.73 ▲ 1.38% USD/NIO 36.62 ▲ 0.63% USD/VES 722.19 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 0.64% USD/TTD 6.75 ▲ 1.19% EUR/BRL 5.79 ▼ 0.44% BRENT 85.21 ▲ 2.29% WTI 79.76 ▲ 2.07% IRON ORE 161.91 — — COPPER 6.37 ▲ 2.15% GOLD 4,058 ▲ 1.53% SILVER 59.12 ▲ 2.57% SOY 1,191 ▼ 0.96% CORN 459.50 ▲ 4.97% WHEAT 644.00 ▲ 2.71% COFFEE 327.00 ▼ 4.22% SUGAR 14.92 ▲ 1.15% ORANGE JUICE 140.90 ▼ 1.16% COTTON 81.68 ▲ 2.32% COCOA 5,936 ▲ 4.21% BEEF 231.58 ▼ 1.34% CATTLE 349.63 ▼ 1.33% LITHIUM 71.58 ▲ 1.91% PETR4 40.66 — 0.00% VALE3 74.01 ▲ 1.59% ITUB4 43.63 ▲ 0.25% BBDC4 18.63 ▼ 0.75% ABEV3 15.81 ▼ 0.13% BBAS3 20.59 ▲ 1.73% B3SA3 15.33 ▲ 1.39% WEGE3 44.20 ▼ 0.43% PRIO3 57.57 ▲ 0.65% SUZB3 41.11 ▼ 0.92% RENT3 40.54 ▲ 0.85% AZZA3 18.85 ▼ 1.93% CSAN3 3.89 ▼ 0.26% RAIZ4 0.31 ▼ 6.06% PCAR3 2.45 ▼ 5.41% GMAT3 3.96 ▲ 0.51% PSSA3 54.29 ▲ 0.46% CVCB3 1.38 ▲ 10.40% POSI3 3.99 — 0.00% SLCE3 13.81 ▼ 0.43% NATU3 8.55 ▼ 0.58% BRKM5 6.83 ▼ 1.59% RANI3 8.01 ▲ 0.75% CSNA3 5.20 ▼ 0.76% CMIN3 5.10 ▼ 6.42% USIM5 8.23 ▼ 1.79% GGBR4 23.32 ▲ 2.19% ENEV3 27.17 ▲ 1.08% CPFE3 47.20 ▲ 0.77% CMIG4 11.20 ▲ 1.17% EQTL3 40.95 ▲ 1.84% LREN3 14.29 ▲ 0.99% VIVT3 35.52 ▲ 2.27% RAIL3 14.13 ▲ 0.14% KLABIN 17.32 ▼ 0.92% RAIA DROGASIL 18.60 ▲ 2.20% RDOR3 36.05 ▲ 1.38% HAPV3 11.19 ▲ 6.98% FLRY3 16.41 ▲ 1.61% SMTO3 16.12 ▼ 1.53% UGPA3 30.11 ▼ 2.65% VBBR3 33.30 ▲ 1.65% BBSE3 40.39 ▲ 0.27% BPAC11 57.95 ▲ 0.75% CURY3 33.59 ▲ 1.42% AERI3 2.07 ▼ 0.48% VIVARA 23.43 ▲ 1.38% COMPASS 25.20 ▲ 1.74% VAMOS 3.15 ▲ 4.30% SANB11 27.34 ▼ 0.11% ASAI3 8.66 ▼ 0.57% SBSP3 30.34 ▼ 0.10% WALMEX 49.32 ▼ 0.66% GMEXICO 199.61 ▲ 2.06% FEMSA 232.52 ▲ 3.18% CEMEX 22.24 ▲ 2.11% GFNORTE 186.00 ▲ 2.16% BIMBO 56.55 ▲ 1.22% TELEVISA 9.49 ▼ 1.25% AMX 22.83 ▲ 1.06% GAP 394.05 ▼ 3.46% ASUR 275.61 ▼ 1.09% OMA 235.49 ▲ 0.93% KOF 180.00 ▼ 0.92% GRUMA 280.31 ▼ 0.38% KIMBER 38.53 ▲ 0.81% SQM-B 67,900 ▲ 1.03% COPEC 6,210 ▲ 2.52% BSANTANDER 78.64 ▲ 0.56% FALABELLA 5,875 ▼ 0.51% ENELAM 85.75 ▲ 1.84% CENCOSUD 2,040 — 0.00% CMPC 1,103 ▲ 2.32% BANCO CHILE 189.50 ▲ 2.43% LATAM AIR 24.90 — 0.00% YPF 77,775 ▲ 0.78% GGAL 7,910 ▼ 2.10% PAMPA 5,230 ▲ 0.10% TXAR 662.00 ▼ 0.38% ALUAR 949.00 ▼ 1.61% TGS 9,710 ▲ 1.46% CEPU 2,327 ▲ 0.35% MIRGOR 16,750 ▼ 1.47% COME 45.75 ▲ 2.17% LOMA NEGRA 3,533 ▲ 1.00% BYMA 301.00 ▼ 2.35% TELECOM ARG 4,333 ▲ 1.94% ECOPETROL 16.16 ▲ 1.76% BANCOLOMBIA 82.10 ▲ 2.09% GRUPO AVAL 4.95 ▲ 0.81% CREDICORP 392.24 ▲ 0.78% SOUTHERN COPPER 182.38 ▲ 4.50% BUENAVENTURA 31.03 ▲ 4.06% MERCADOLIBRE 1,874 ▲ 0.35% NUBANK 13.99 ▲ 2.34% XP 16.87 ▲ 3.05% PAGSEGURO 9.28 — 0.00% STONE 11.30 ▲ 1.35% GLOBANT 30.92 ▼ 3.74% TECNOGLASS 44.19 ▲ 3.15% GAP AIRPORT 225.95 ▼ 2.93% ASUR 275.61 ▼ 1.09% OMA AIRPORT 107.64 ▲ 1.42% AMX ADR 26.18 ▲ 0.58% FEMSA ADR 133.17 ▲ 3.22% CEMEX ADR 12.80 ▲ 2.81% PETROBRAS ADR 17.92 ▲ 0.22% VALE ADR 14.59 ▲ 2.89% ITAU ADR 8.55 ▲ 0.94% SANTANDER BR 5.40 ▲ 0.84% AMBEV ADR 3.09 ▲ 0.98% CSN 1.04 ▲ 0.49% GERDAU 4.61 ▲ 2.67% LATAM ADR 53.51 ▲ 0.34% BTC 64,942 ▲ 4.34% ETH 1,887 ▲ 6.38% SOL 77.68 ▲ 3.77% XRP 1.11 ▲ 4.19% BNB 581.34 ▲ 2.60% ADA 0.16 ▲ 4.75% DOGE 0.07 ▲ 3.48% AVAX 6.65 ▲ 3.19% LINK 8.32 ▲ 5.73% DOT 0.85 ▲ 1.85% LTC 45.43 ▲ 4.46% BCH 236.54 ▲ 0.13% TRX 0.33 ▲ 0.53% XLM 0.18 ▲ 2.23% HBAR 0.07 ▲ 1.03% NEAR 2.01 ▲ 4.55% ATOM 1.56 ▲ 1.56% AAVE 98.70 ▲ 4.60% SELIC 14.25% EMBRAER 82.49 ▼ 0.63% EMBRAER ADR 64.91 ▲ 0.67% JBS 11.83 ▲ 0.25% JBS BDR 59.75 ▼ 1.42% MBRF3 16.09 ▲ 2.35% MBRFY 3.14 ▲ 2.95% INTER 5.70 ▲ 0.89% EGX 52,299 ▼ 0.59% USD/ZAR 16.37 ▲ 0.17% USD/NGN 1,381 — 0.00% NIKKEI 67,744 ▲ 0.74% CSI300 4,797 ▲ 2.15% HSI 24,341 ▲ 0.52% NIFTY 24,052 ▼ 0.66% KOSPI 6,857 ▲ 0.73% JCI 6,040 ▲ 0.03% USD/JPY 162.20 — 0.00% USD/CNY 6.7624 — 0.00% DAX 25,147 ▲ 0.13% CAC 8,367 ▲ 0.03% FTSE 10,529 ▲ 0.30% MIB 52,863 ▲ 0.10% IBEX 19,357 ▲ 0.11% STOXX 642.10 ▲ 0.17% EUR/USD 1.1426 ▲ 0.01% GBP/USD 1.3393 ▲ 0.04% SPX 7,544 ▲ 0.38% DJI 52,508 ▲ 0.02% NDX 29,586 ▲ 1.10% RUT 2,965 ▲ 0.39% TSX 35,321 ▲ 0.19% VIX 16.50 ▼ 3.85% USD/CAD 1.4056 ▼ 0.04% US10Y 4.5850 ▼ 0.52%
since 2009
Tuesday, July 14, 2026

Already 98 new mRNA vaccines against influenza, HIV and more in the pipeline

By · August 18, 2022 · 5 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

Make no mistake: mRNA vaccines are highly controversial. Since they have been used a billion times against Covid-19, the critical voices have not stopped warning and have even become stronger recently.

Previous efforts to create such a vaccine have resulted in antibody-dependent enhancement (ADE), in which immunization made matters worse, not better.

One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →

Read also: Check out our coverage on curated alternative narratives

But people were not told any such thing before being given their shot. And the reason the booster is so urgently being considered? Because, yes, the vaccine is waning. And yes, some people are getting sick. Not just a little ill, but VERY sick.

In addition, we don’t have data on the vaccine’s long-term side effects. Usually, vaccines need 5–10 years before being ready for market. We did those vaccines in 2 years.

Also, those mRNA vaccines are not traditional vaccines, which are attenuated, inactivated, or modified forms of the virus or its antigen. mRNA vaccines are not. They are non-viral vectors containing modified viral RNA that induce the production of antibodies that work also on SARS-CoV-2 infections. Furthermore, mRNA vaccines go inside most cells they encounter, while the virus, attenuated or not, only to specific cells.

BIG PHARMA GOT HOOKED

What is undeniable, however, is that the Covid mRNA vaccine campaign has become a phenomenal financial success for Pfizer, Moderna, and BioNTech, with sales and profits soaring. It is no wonder that this formula will also be used for other diseases.

By 2020, all attempts to establish mRNA therapies failed because of the severe side effects with questionable efficacy. The Corona pandemic brought a breakthrough.

Dr. Robert Malone reports that a simple search of the government websites where clinical trials are reported – ClinicalTrials.gov – shows many new trials started or are about to start. A simple search for the term ‘mRNA vaccine’ revealed 98 clinical trials that have not yet started and are currently recruiting.

So which clinical trials are we talking about? The government website lists 81 clinical trials with the search term mRNA vaccines that are currently recruiting participants (linked here).

These include clinical trials for Covid-19, influenza (alone and in combination with Covid-19 mRNA vaccines), HIV, leukemia, RSV pneumococcal, EBV, HPV, CMV, Zika, metapneumovirus, and human parainfluenza infection. These clinical trials also include safety studies in vulnerable populations and children.

Since these clinical trials are already underway, that means they have already passed preclinical testing. Malone believes that many of the “normal” requirements for preclinical testing of a vaccine or gene therapy product have been bypassed because enrollment could occur so quickly.

We know that the “mRNA” from these vaccines incorporating the synthetic nucleotide pseudouridine can persist in lymph nodes for at least 60 days after injection.

Then there are issues with the distribution of the lipid nanoparticles and the toxicity associated with that, including reproductive safety and crossing the blood-brain barrier.

RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Since we know from Pfizer’s data package that inherent safety problems with these vaccines were swept under the rug as part of the emergency or conditional approval process and that these problems should have been a red flag in other clinical trials of mRNA vaccines, it is hard to believe that even one of these problems was addressed.

Especially since many of the underlying problems with these vaccines have only recently been discovered, and the number of adverse events and publications highlighting the dangers continues to grow.

On the UChealth today website, the article “Clinical trials for ‘all-new’ mRNA flu vaccines start soon. Will they work better?” sings its praises

It states:

An entirely new type of flu vaccine could better protect people from influenza, and clinical trials of the vaccines are starting this month.

The new flu vaccines are based on mRNA technology, the same method used to create the most common and successful U.S. COVID-19 vaccines by Pfizer and Moderna.

These vaccines use messenger RNA (or mRNA) to “teach” cells to make proteins. These proteins don’t cause illness but are the same type that we’d get during a COVID-19 or flu infection. The vaccines then train the immune system to prevent actual infections.

Apparently, trials have already begun in the U.S. state of Colorado with 50 people aged 65 to 85.

It goes on to say:

At this time, Dr. Myron Levin, an infectious disease and vaccine expert, expects to enroll older adults for the first round of testing at the University of Colorado’s Anschutz Medical Campus. 

In the coming weeks, Levin also expects to recruit volunteers for another clinical trial related to mRNA flu vaccines. Moderna has developed a new vaccine designed to provide combined protection against influenza and COVID-19, including the latest variants of COVID-19.

“These vaccines have worked for COVID-19. Now vaccine makers are asking what other problems we have in the world. Could mRNA vaccines help prevent influenza, shingles, RSV, and even Ebola? The potential to combat a particular pathogen is endless,” said Levin.

VACCINES ARE A BETTER BUSINESS THAN OTHER DRUGS

Pharmaceuticals are a huge business. That’s why they fight anything that makes them unnecessary, such as vitamins, hormones, micronutrients, and healthy foods.

But the crux of it is that you first need sick people to sell pharmaceuticals to or implant stents and pacemakers instead of providing them with potassium, magnesium, and vitamins.

That’s why vaccines are a brilliant business idea because you can sell them to healthy people. According to the latest business model, you use politicians and the state bureaucracy as distributors to do this, so you only have one bill to submit and leave the rest of the work, including collecting payments from taxpayers to the state.

And another advantage fits well into the increasingly authoritarian trend that has gripped the world. Since apparently someone has to check whether everyone has been vaccinated, the government needs the vaccination card, it is argued, but it is just as well suited to meticulously controlling and monitoring everyone.

During the Covid event, many health officials already declared, “If the Covid app is red, you can’t go anywhere.” And China’s CCP added, “…and you won’t get any more money from the bank either.” That’s what the social credit system is for.

Join us on Telegram: t.me/theriotimes

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.